Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review

Rheumatology (Oxford). 2018 Nov 1;57(11):2055-2057. doi: 10.1093/rheumatology/key228.

Authors

Mathilde Guillot¹, Cedric Rafat², David Buob³, Paul Coppo⁴, Matthieu Jamme², Eric Rondeau², Olivier Fain¹, Arsène Mekinian¹

Affiliations

¹ AP-HP, Hôpital Saint-Antoine, service de médecine interne and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Sorbonne Universités, Paris, France.
² AP-HP, Hôpital Tenon, service de néphrologie, Sorbonne Universités, Paris, France.
³ AP-HP, Hôpital Tenon, service d'anatomopathologie, Sorbonne Universités, Paris, France.
⁴ AP-HP, Hôpital Saint-Antoine, service d'hématologie, Sorbonne Universités, Paris, France.

PMID: 30101319
DOI: 10.1093/rheumatology/key228

No abstract available

Publication types

Case Reports
Letter
Review

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Antiphospholipid Syndrome / drug therapy*
Catastrophic Illness
Female
Humans
Immunologic Factors / therapeutic use*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
eculizumab